Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $13.1 million.

  • Anika Therapeutics' Share-based Compensation fell 38.63% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 32.74%. This contributed to the annual value of $13.1 million for FY2024, which is 13.86% down from last year.
  • Latest data reveals that Anika Therapeutics reported Share-based Compensation of $13.1 million as of FY2024, which was down 13.86% from $15.2 million recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Share-based Compensation registered a high of $15.2 million during FY2023, and its lowest value of $5.4 million during FY2020.
  • Its 3-year average for Share-based Compensation is $14.2 million, with a median of $14.3 million in 2022.
  • As far as peak fluctuations go, Anika Therapeutics' Share-based Compensation spiked by 105.81% in 2021, and later dropped by 13.86% in 2024.
  • Yearly analysis of 5 years shows Anika Therapeutics' Share-based Compensation stood at $5.4 million in 2020, then skyrocketed by 105.81% to $11.1 million in 2021, then increased by 29.14% to $14.3 million in 2022, then grew by 6.48% to $15.2 million in 2023, then fell by 13.86% to $13.1 million in 2024.